InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Poly(I:C) (HMW) / LyoVec™ | C/EBPβ deficiency enhances the keratinocyte innate immune response to direct ... | 2023 | Innate Immun. | House J.S. et al. | DOI: 10.1177/17534259231162192 |
| Poly(dA:dT) | C/EBPβ deficiency enhances the keratinocyte innate immune response to direct ... | 2023 | Innate Immun. | House J.S. et al. | DOI: 10.1177/17534259231162192 |
| pFUSE-hIgG2-Fc | Development of anti-feline PD-1 antibody and its functional analysis. | 2023 | Sci Rep. | Nishibori S. et al. | DOI: 10.1038/s41598-023-31543-6 |
| RAW-Lucia™ ISG Cells | Self-replicating RNA nanoparticle vaccine elicits protective immune responses... | 2023 | Mol Ther Nucleic Acids | Lin G. et al. | DOI: 10.1016/j.omtn.2023.04.021 |
| PlasmoTest™ - Mycoplasma Detection Kit | MicroRNA-196-5p targets Derlin-1 to induce autophagy in human osteosarcoma ce... | 2023 | Acta Biochim Pol. | Ji Z. et al. | DOI: 10.18388/abp.2020_6551 |
| THP1-Dual™ Cells | Tau activation of microglial cGAS-IFN reduces MEF2C-mediated cognitive resili... | 2023 | Nat Neurosci. | Udeochu J.C. et al. | DOI: 10.1038/s41593-023-01315-6 |
| QUANTI-Blue™ | Tau activation of microglial cGAS-IFN reduces MEF2C-mediated cognitive resili... | 2023 | Nat Neurosci. | Udeochu J.C. et al. | DOI: 10.1038/s41593-023-01315-6 |
| 2'3'-cGAMP | Tau activation of microglial cGAS-IFN reduces MEF2C-mediated cognitive resili... | 2023 | Nat Neurosci. | Udeochu J.C. et al. | DOI: 10.1038/s41593-023-01315-6 |
| QUANTI-Luc™: Luciferase Detection Reagent | Tau activation of microglial cGAS-IFN reduces MEF2C-mediated cognitive resili... | 2023 | Nat Neurosci. | Udeochu J.C. et al. | DOI: 10.1038/s41593-023-01315-6 |
| THP1-Dual™ KO-cGAS Cells | Tau activation of microglial cGAS-IFN reduces MEF2C-mediated cognitive resili... | 2023 | Nat Neurosci. | Udeochu J.C. et al. | DOI: 10.1038/s41593-023-01315-6 |
| Puromycin | 3D genome mapping identifies subgroup-specific chromosome conformations and t... | 2023 | Nat Commun. | Okonechnikov K. et al. | DOI: 10.1038/s41467-023-38044-0 |
| RAW-Blue™ Cells | The Use of Chitosan Nanoparticles for Delivery of CpG ODN in Treatment of All... | 2023 | Rep Biochem Mol Biol. | Iswanti F.C. et al. | DOI: 10.52547/rbmb.11.4.599 |
| Alhydrogel® adjuvant 2% | The Use of Chitosan Nanoparticles for Delivery of CpG ODN in Treatment of All... | 2023 | Rep Biochem Mol Biol. | Iswanti F.C. et al. | DOI: 10.52547/rbmb.11.4.599 |
| QUANTI-Blue™ | The Use of Chitosan Nanoparticles for Delivery of CpG ODN in Treatment of All... | 2023 | Rep Biochem Mol Biol. | Iswanti F.C. et al. | DOI: 10.52547/rbmb.11.4.599 |
| Alhydrogel® adjuvant 2% | A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Pot... | 2023 | Vaccines (Basel) | Campbell E. et al. | DOI: 10.3390/vaccines11040832 |
| ODN 1826 VacciGrade™ | A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Pot... | 2023 | Vaccines (Basel) | Campbell E. et al. | DOI: 10.3390/vaccines11040832 |
| AddaVax™ | Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-Co... | 2023 | Vaccines (Basel) | Shi J. et al. | DOI: 10.3390/vaccines11040713 |
| TLR4-based adjuvant - MPLA-SM VacciGrade™ | Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-Co... | 2023 | Vaccines (Basel) | Shi J. et al. | DOI: 10.3390/vaccines11040713 |
| Alhydrogel® adjuvant 2% | Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-Co... | 2023 | Vaccines (Basel) | Shi J. et al. | DOI: 10.3390/vaccines11040713 |
| Imiquimod VacciGrade™ (R837) | Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-Co... | 2023 | Vaccines (Basel) | Shi J. et al. | DOI: 10.3390/vaccines11040713 |